Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112

1.

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.

Bhattacharyya S, Ahmed AT, Arnold M, Liu D, Luo C, Zhu H, Mahmoudiandehkordi S, Neavin D, Louie G, Dunlop BW, Frye MA, Wang L, Weinshilboum RM, Krishnan RR, Rush AJ, Kaddurah-Daouk R.

Transl Psychiatry. 2019 Jul 4;9(1):173. doi: 10.1038/s41398-019-0507-5.

2.

Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care - The reality of treatment resistant-based therapies.

Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B.

J Psychiatr Res. 2019 Jul;114:211-213. doi: 10.1016/j.jpsychires.2019.04.027. Epub 2019 Apr 27. No abstract available.

PMID:
31101328
3.

The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis.

Boschloo L, Bekhuis E, Weitz ES, Reijnders M, DeRubeis RJ, Dimidjian S, Dunner DL, Dunlop BW, Hegerl U, Hollon SD, Jarrett RB, Kennedy SH, Miranda J, Mohr DC, Simons AD, Parker G, Petrak F, Herpertz S, Quilty LC, John Rush A, Segal ZV, Vittengl JR, Schoevers RA, Cuijpers P.

World Psychiatry. 2019 Jun;18(2):183-191. doi: 10.1002/wps.20630.

4.

Recall accuracy for the symptoms of a major depressive episode among clinical trial participants.

Dunlop BW, Granros M, Lechner A, Mletzko-Crowe T, Nemeroff CB, Mayberg HS, Craighead WE.

J Psychiatr Res. 2019 Sep;116:178-184. doi: 10.1016/j.jpsychires.2019.03.008. Epub 2019 Mar 8.

PMID:
30878146
5.

49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial.

Greden JF, Rosthschild AJ, Thase M, Dunlop BW, DeBattista DC, Conway CR, Forester BP, Mondimore FM, Shelton RC, Li J, Gilbert A, Burns L, Jablonski M, Dechairo B, Parikh S.

CNS Spectr. 2019 Feb;24(1):202-203. doi: 10.1017/S1092852919000415.

PMID:
30859976
6.

Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients.

Jovanovic T, Duncan EJ, Kaye J, Garza K, Norrholm SD, Inslicht SS, Neylan TC, Mathew SJ, Iosifescu D, Rothbaum BO, Mayberg HS, Dunlop BW.

Psychophysiology. 2019 Feb 26:e13356. doi: 10.1111/psyp.13356. [Epub ahead of print]

PMID:
30807663
7.

Moving pharmacoepigenetics tools for depression toward clinical use.

Hack LM, Fries GR, Eyre HA, Bousman CA, Singh AB, Quevedo J, John VP, Baune BT, Dunlop BW.

J Affect Disord. 2019 Apr 15;249:336-346. doi: 10.1016/j.jad.2019.02.009. Epub 2019 Feb 6. Review.

PMID:
30802699
8.

Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Dunlop BW, LoParo D, Kinkead B, Mletzko-Crowe T, Cole SP, Nemeroff CB, Mayberg HS, Craighead WE.

Am J Psychiatry. 2019 Apr 1;176(4):275-286. doi: 10.1176/appi.ajp.2018.18091075. Epub 2019 Feb 15.

PMID:
30764648
9.

Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.

Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B.

J Psychiatr Res. 2019 Apr;111:59-67. doi: 10.1016/j.jpsychires.2019.01.003. Epub 2019 Jan 4.

10.

Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.

Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW.

Pharmacogenomics. 2019 Jan;20(1):37-47. doi: 10.2217/pgs-2018-0142. Epub 2018 Dec 6.

PMID:
30520364
11.

When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates.

Maples-Keller JL, Jovanovic T, Dunlop BW, Rauch S, Yasinski C, Michopoulos V, Coghlan C, Norrholm S, Rizzo AS, Ressler K, Rothbaum BO.

J Anxiety Disord. 2019 Jan;61:89-97. doi: 10.1016/j.janxdis.2018.10.006. Epub 2018 Oct 29.

PMID:
30502903
12.

DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder.

Pape JC, Carrillo-Roa T, Rothbaum BO, Nemeroff CB, Czamara D, Zannas AS, Iosifescu D, Mathew SJ, Neylan TC, Mayberg HS, Dunlop BW, Binder EB.

Clin Epigenetics. 2018 Nov 3;10(1):136. doi: 10.1186/s13148-018-0569-x.

13.

The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions.

Dunlop BW, Wong A.

Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:361-379. doi: 10.1016/j.pnpbp.2018.10.010. Epub 2018 Oct 17. Review.

PMID:
30342071
14.

2018 American Society of Consultant Pharmacists Annual Meeting & Exhibition.

Bridgeman M, Prete D, Rolston N, Abazia D, Sturgill M, Finn L, Summers D, Marvanova M, Henkel P, Thompson J, Dewey M, Friesner D, Marvanova M, Alessi C, Cuellar L, Yamagishi L, O'Neil C, Erickson O, Mazzei K, Kamal K, Early N, Bainter B, Hanson L, Schmitz E, Loomis A, Norberto M, Hume A, Meyer M, Batra R, Likar D, Enguidanos S, Liu C, Kotansky B, Fisher A, Ruby CM, Pruskowski J, Karim SNA, Yong BSW, Alessi C, Cuellar L, Slattum P, Crouse E, Delafuente J, Donohoe K, Ogbonna K, Peron E, Powers K, Price E, Zimmerman K, Rahim S, Gendron T, Slattum P, Donohoe K, Cho C, Zimmerman K, Crouse E, Peron E, Powers K, Price E, Slattum P, Donohoe K, Elliott L, Minter C, Morin M, Marshall L, Stevens G, Cordaro C, Hill M, Nagy K, Kroustos KR, Sobota KF, Mahan R, Bailey T, Ioannou K, Mansour D, Thompson T, Chatellier K, Schwenk A, Ruby C, Chen TS, Li S, James M, Spilios M, Leschak A, Levine A, Forgette S, Oluigbo N, Szollosi D, Avalime D, Weaver SB, Maneno M, Ettienne E, Yi JY, Hart L, Gray S, Ozalas S, Miller K, Dave R, Bork J, Emmelhainz J, Adams K, Postolski J, Willoughby M, Feldman E, Braham K, Miller C, Barbagallo D, Seabury R, Noviasky J, Alessi C, Cuellar L, Dabhi J, Bartlett D, Le T, Simoni-Wastila L, Kuzucan A, Simoni-Wastila L, Le T, Park S, Simoni-Wastila L, Le T, Park S, Choi M, Simoni-Wastila L, Park S, Le T, Choi M, Simoni-Wastila L, Khokhar B, Choi M, Le T, Simoni-Wastila L, Brody P, Hejna M, Mason J, Graham M, Micceri J, Lypska R, Quinn B, Wilson H, Wahler R, Aloyo M, Tomm V, Hill A, Obringer A, Butterfoss K, Blak J, Balcer R, Boza J, Foster A, Shafique E, Kleven C, Wigle P, Brown B, Alessi C, Cuellar L, Meyer K, Mobley-Bukstein W, Singh H, Perez E, Mira AE, Kuehner W, Czechowski L, Cook H, Brandt N, Parson J, Fornaro R, Brandt N, Claeys K, Zarowitz B, Mansour D, McFadden C, Simpkins S, Ojowa F, Klutts A, Holmes S, Smith E, Cornman JR, Doran K, Resnick B, Brandt N, Umeozulu C, Williams A, Brandt N, Hennawi G, Thomas D, Gerber DK, Meyer K, Sharma K, Cooke C, Howard A, Chater R, Vogler A, Brandt N, Kennett-Hayes K, Elliott L, Engelbert J, Hargrave E, Bambico C, Patel K, Warriner C, Slattum P, Desai NR, Rowan CG, Alvarez P, Fogli J, Toto RD, Desai NR, Alvarez P, Fogli J, Reed P, Owens MK, Greden JF, Rothschild AJ, Zandy S, Thase M, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Li J, Gilbert A, Burns L, Jablonski M, Dechairo B, Parikh S, Donohue J, Feldman G, Sethi S, Barnes C, Pendyala S, Bourdet D, Ferguson G, Barnes C, Pendyala S, Crater G, Fogli J, Mayo M, Gross C, Miyawa J, Ono R, Woods S, Garza D, Panov N, Fogli J, Moran E, Sabesan V, Wertman J, Ngim K.

Consult Pharm. 2017 Oct 1;33(10):572-608.

PMID:
30322434
15.

Model structure for protocol adherence utilizing a manualized therapeutic massage intervention.

Larson ER, Kinkead B, Edwards SA, Schettler PJ, Dunlop BW, Rakofsky JJ, Rapaport MH.

J Complement Integr Med. 2018 Oct 12;16(2). pii: /j/jcim.2019.16.issue-2/jcim-2016-0118/jcim-2016-0118.xml. doi: 10.1515/jcim-2016-0118.

PMID:
30312159
16.

Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse.

Kelley ME, Dunlop BW, Nemeroff CB, Lori A, Carrillo-Roa T, Binder EB, Kutner MH, Rivera VA, Craighead WE, Mayberg HS.

Depress Anxiety. 2018 Oct;35(10):992-1000. doi: 10.1002/da.22832. Epub 2018 Sep 7.

17.

Neuroimaging Advances for Depression.

Dunlop BW, Mayberg HS.

Cerebrum. 2017 Nov 1;2017. pii: cer-16-17. eCollection 2017 Nov-Dec.

18.

Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder.

Dunlop BW, Polychroniou PE, Rakofsky JJ, Nemeroff CB, Craighead WE, Mayberg HS.

Psychol Med. 2019 Aug;49(11):1869-1878. doi: 10.1017/S0033291718002568. Epub 2018 Sep 12.

PMID:
30207254
19.

Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response.

Syed SA, Beurel E, Loewenstein DA, Lowell JA, Craighead WE, Dunlop BW, Mayberg HS, Dhabhar F, Dietrich WD, Keane RW, de Rivero Vaccari JP, Nemeroff CB.

Neuron. 2018 Sep 5;99(5):914-924.e3. doi: 10.1016/j.neuron.2018.08.001. Epub 2018 Aug 23.

20.

Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder.

Gould F, Dunlop BW, Rosenthal JB, Iosifescu DV, Mathew SJ, Neylan TC, Rothbaum BO, Nemeroff CB, Harvey PD.

Arch Clin Neuropsychol. 2019 Jun 1;34(4):539-547. doi: 10.1093/arclin/acy064.

Supplemental Content

Loading ...
Support Center